Contact Us
Developing effective therapies for central nervous system (CNS) disorders remains one of the greatest challenges in pharmaceutical research. Despite significant advances in genetics, molecular biology, and disease modeling, many drug candidates that show promise in preclinical studies ultimately fail during clinical trials. One contributing factor is the difficulty of accurately predicting how a potential therapy will affect the function of human neural networks.
For decades, CNS drug discovery has relied heavily on molecular and structural biomarkers to evaluate potential treatments. Researchers routinely measure changes in gene expression, protein levels, cell viability, and tissue morphology to determine whether a drug is having the desired biological effect. While these measurements provide valuable information, they do not always reveal whether neurons are communicating normally or whether neural circuits have regained healthy function.
This is where functional readouts are becoming increasingly important.
Functional biomarkers measure the physiological activity of living neurons, providing direct insight into how neural networks respond to disease or therapeutic intervention. In neurological disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, schizophrenia, and autism spectrum disorder, changes in neuronal signaling and network connectivity often occur before obvious structural changes are detected. Measuring these functional changes can provide a more complete understanding of disease progression and therapeutic efficacy.
Electrophysiology is one of the most powerful approaches for generating functional biomarkers. By recording the electrical activity of neurons, researchers can evaluate neuronal firing, network synchronization, oscillatory behavior, and connectivity within brain tissue. These measurements help determine whether a treatment is restoring normal neural function rather than simply altering molecular markers.
As neurological drug screening continues to evolve, researchers are also adopting more physiologically relevant disease models, including human brain organoids. These three-dimensional models better mimic aspects of human brain development and disease, making them valuable tools for evaluating candidate therapeutics. However, to fully realize their potential, organoids must be assessed using functional assays that capture neural activity in addition to structural and molecular characteristics.
The SomaFocus™ platform was developed to provide these critical functional readouts. By enabling automated electrophysiological recordings from within intact brain organoids, SomaFocus measures neuronal spiking and local field potentials without requiring slicing, plating, or extensive sample preparation. This allows researchers to evaluate neural network activity while preserving the organoid's native three-dimensional architecture.
As the field of translational neuroscience continues to advance, integrating functional biomarkers into preclinical workflows may help improve confidence in disease models and strengthen decision-making during therapeutic development. Combining molecular, structural, and electrophysiological data gives researchers a more comprehensive view of how candidate drugs influence neural function, ultimately supporting the development of therapies with greater potential for clinical success.
The future of CNS drug discovery depends not only on understanding what cells look like or which genes they express, but also on understanding how they function together as living neural networks. Functional readouts are becoming an essential component of that process.